22 Recruiting Chronic Lymphocytic Leukemia (CLL) Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Chronic Lymphocytic Leukemia (CLL)
Related Conditions
Top Recruiting Chronic Lymphocytic Leukemia (CLL) Studies
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
📍 Stanford University Medical Center (Data collection only) — Stanford, California
View Study & Checklist ➔Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
📍 Memorial Sloan Kettering Basking Ridge (All protocol activities) — Basking Ridge, New Jersey
View Study & Checklist ➔A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
📍 Stamford Hospital/Bennett Cancer Center — Stamford, Connecticut
View Study & Checklist ➔A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
📍 UT MD Anderson — Houston, Texas
View Study & Checklist ➔Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
📍 New England Cancer Specialists — Scarborough, Maine
View Study & Checklist ➔A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
📍 City of Hope — Duarte, California
View Study & Checklist ➔A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
📍 City of Hope — Duarte, California
View Study & Checklist ➔A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
📍 City of Hope — Duarte, California
View Study & Checklist ➔Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
📍 Research Site — Boston, Massachusetts
View Study & Checklist ➔A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
📍 Center for International Blood and Marrow Transplant Research (CIBMTR) — Milwaukee, Wisconsin
View Study & Checklist ➔Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
📍 Northwestern University — Evanston, Illinois
View Study & Checklist ➔Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
📍 Moores Cancer Center at UC San Diego /ID# 230157 — La Jolla, California
View Study & Checklist ➔